Quantification of Aerosol Particle Concentrations During Endoscopic Sinonasal Surgery in the Operating Room.
CONCLUSION: Drilling and microdebrider use during endonasal surgery in a standard operating room is associated with a significant increase in airborne particle concentrations. Fortunately, this increase in aerosol concentration is localized to the area of the operating surgeon, with no detectable increase in aerosol particles at other OR positions. PMID: 33012174 [PubMed - as supplied by publisher]
In a report published Oct. 8 in the New England Journal of Medicine, researchers confirmed the benefits of remdesivir for treating people hospitalized for COVID-19. Remdesivir, an antiviral drug, has emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for treating anyone hospitalized for COVID-19. That authorization means that doctors can prescribe the intravenous (IV) drug for people who are infected with SARS-CoV-2 and have been hospitalized. While the drug was initially authorized only for those who needed supplemental oxygen or ventilators to breathe, an expanded EUA from the FDA in late ...
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
We thank Zwaveling et al1 for appreciating our review2 and for their insightful correspondence. They suggest that suppression of angiotensin-converting enzyme-2 (ACE-2) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could impair the hydrolysis of des-Arg9-bradykinin and stimulate the bradykinin recepto r type 1 (BKB1) pathway to induce leakage of fluid into the lungs. In support of their hypothesis, they stated that loss of ACE-2 in an animal model aggravated acid-induced pulmonary edema, and these effects are alleviated by administration of recombinant human ACE-2.
Jian et al1 in a recent article refer to the immune reaction of the upper respiratory tract (URT) in patients infected by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 (coronavirus disease 2019 [COVID-19] pandemic). The authors wonder about the consequences of inhaled corticosteroids (ICSs) o n immune reaction. We share the queries of Jian et al, from a practical point of view.
Capsule Summary: Clinical data from 94 SARS-CoV-2-infected individuals affected by inborn errors of immunity provide initial insights into the requirements and redundancies of immune pathways in host defense against and severity of SARS-CoV-2 infection.
ConclusionThe MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV further investigated experimentally, it would be an effective vaccine candidate against SARS-CoV-2 to control and prevent COVID-19.
Conditions: COVID; COVID-19; SARS-CoV-2; SARS (Severe Acute Respiratory Syndrome) Interventions: Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Other: Placebo; Drug: Remdesivir Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); The International Network for Strategic Initiatives in Global HIV Trials Not yet recruiting
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
A better understanding of the pathogenesis and pathology of SARS-CoV-2 in fatal cases could help guide future therapeutic and prevention strategies.Emerging Infectious Diseases